DEF 14A: Axsome Therapeutics Sets Date for 2024 Annual Stockholders Meeting

Axsome Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 7, 2024, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.

Summary

• Axsome Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 7, 2024.
• Stockholders of record as of April 15, 2024, are entitled to vote.
• The meeting will include the election of two Class III directors, ratification of Deloitte & Touche LLP as the independent accounting firm for the year ending December 31, 2024, and a non-binding advisory vote on executive compensation.
• The Board of Directors recommends voting for the director nominees, ratifying the appointment of Deloitte & Touche LLP, and approving the compensation of the named executive officers.
• The proxy statement and annual report are available online at www.proxyvote.com.
• The company's Board of Directors currently consists of five members.
• The company's non-employee directors receive an annual cash retainer and an annual equity retainer.
• The company's CEO pay ratio is estimated to be 38:1.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, presenting factual information in a neutral tone. The positive sentiment is driven by the company's commitment to corporate responsibility and ethical standards.

Positives

• The Board of Directors is committed to having a diversified board.
• The company has adopted a Code of Business Conduct and Ethics that applies to all employees, officers, and directors.
• The company has a clawback policy related to the recovery of erroneously awarded incentive-based compensation.
• The company has an insider trading policy that prohibits short sales and derivative transactions of the company's stock by its NEOs, directors and all of its employees.

Risks

• The classification of the Board of Directors into three classes with staggered three-year terms may have the effect of delaying or preventing changes in our control or management.
• The company faces a number of risks, including risks relating to its operations, strategic direction and intellectual property.

Future Outlook

The company is committed to an ongoing focus on ESG issues during 2024 and beyond.

Management Comments

• Your vote is important to us.
• Please act as soon as possible to vote your shares.
• Thank you for your ongoing support of Axsome.

Industry Context

The document provides standard information related to corporate governance and executive compensation, which is typical for publicly traded companies in the biopharmaceutical industry.

Comparison to Industry Standards

• The peer group used for executive compensation benchmarking includes companies like ACADIA Pharmaceuticals, Intra-Cellular Therapies, and Sage Therapeutics.
• Axsome ranked at the 43rd percentile of current market cap and at the 18th percentile of trailing four quarters revenue of the peer group as of August 2022.

Related Party Transactions

• The company has license agreements with Antecip Bioventures II LLC, an entity owned by the CEO, requiring royalty payments equal to 3.0% of net sales of products containing the licensed technology.

Stakeholder Impact

• The document provides information relevant to stockholders regarding voting rights and corporate governance.
• The executive compensation discussion is relevant to stakeholders interested in the alignment of executive pay with company performance.

Next Steps

• Stockholders are encouraged to vote on the proposals outlined in the proxy statement.
• The Board of Directors will consider the outcome of the advisory vote on executive compensation when making future compensation arrangements.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Executive Compensation, Board of Directors, Director Election, Deloitte & Touche, Stockholders, Corporate Governance, Axsome Therapeutics